On October 8, the FDA approved cemiplimab-rwlc for the adjuvant treatment of adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation. For more information, read the FDA announcement and the Regeneron Pharmaceuticals press release.
On October 8, the FDA approved cemiplimab-rwlc for the adjuvant treatment of adults with cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.
For more information, read the FDA announcement and the Regeneron Pharmaceuticals press release.
Posted on 10/9/2025
At the 2026 ASCO Annual Meeting, the Louisiana Oncology Society received the ASCO Jeffrey C Ward Affiliate Advocacy Award for advancing critical advocacy priorities that have translated into meaningful legislative victories. The Iowa Oncology Society and Washington State Medical Oncology Society were also recognized for their advocacy efforts in 2025 at the meeting, receiving second place awards.
